Cleara Biotech, a company pioneering a novel approach for the treatment of pan-mutation-p53 cancers by selectively clearing cells in which the p53 protein has become impaired, today announced that the United States Patent and Trademark Office (USPTO) has granted a composition of matter patent (US Patent 12,653,862) covering a broad range of its all-D amino acid cell-penetrating peptides (CPPs), including CL04183, the Company’s lead candidate for the treatment of mutant-p53-driven pathologies, including metastatic colorectal, ovarian, breast cancers and non-melanoma skin cancers.
